Literature DB >> 24449420

Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.

Huamei He1, Hai Tao, Hui Xiong, Sheng Zhong Duan, Francis X McGowan, Richard M Mortensen, James A Balschi.   

Abstract

This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, causes cardiotoxicity independently of PPARγ. Energy metabolism and mitochondrial function were measured in perfused hearts isolated from C57BL/6, cardiomyocyte-specific PPARγ-deficient mice, and their littermates. Cardiac function and mitochondrial oxidative stress were measured in both in vitro and in vivo settings. Treatment of isolated hearts with RSG at the supratherapeutic concentrations of 10 and 30 μM caused myocardial energy deficiency as evidenced by the decreases in [PCr], [ATP], ATP/ADP ratio, energy charge with a concomitant cardiac dysfunction as indicated by the decreases in left ventricular systolic pressure, rates of tension development and relaxation, and by an increase in end-diastolic pressure. When incubated with tissue homogenate or isolated mitochondria at these same concentrations, RSG caused mitochondrial dysfunction as evidenced by the decreases in respiration rate, substrate oxidation rates, and activities of complexes I and IV. RSG also increased complexes I- and III-dependent O₂⁻ production, decreased glutathione content, inhibited superoxide dismutase, and increased the levels of malondialdehyde, protein carbonyl, and 8-hydroxy-2-deoxyguanosine in mitochondria, consistent with oxidative stress. N-acetyl-L-cysteine (NAC) 20 mM prevented RSG-induced above toxicity at those in vitro settings. Cardiomyocyte-specific PPARγ deletion and PPARγ antagonist GW9662 did not prevent the observed cardiotoxicity. Intravenous injection of 10 mg/kg RSG also caused cardiac dysfunction and oxidative stress, 600 mg/kg NAC antagonized these adverse effects. In conclusion, this study demonstrates that RSG at supratherapeutic concentrations causes cardiotoxicity via a PPARγ-independent mechanism involving oxidative stress-induced mitochondrial dysfunction in mouse hearts.

Entities:  

Keywords:  PPARγ; Rosiglitazone; cardiac function; energy metabolism; mitochondria; oxidative stress

Mesh:

Substances:

Year:  2014        PMID: 24449420      PMCID: PMC4243497          DOI: 10.1093/toxsci/kfu015

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  66 in total

1.  Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.

Authors:  M McMorran; D Vu
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

Review 2.  Thiazolidinediones: a new class of antidiabetic drugs.

Authors:  C Day
Journal:  Diabet Med       Date:  1999-03       Impact factor: 4.359

3.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

4.  Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart.

Authors:  Siripong Palee; Punate Weerateerangkul; Sirirat Surinkeaw; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Exp Physiol       Date:  2011-06-10       Impact factor: 2.969

5.  Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.

Authors:  Mariel Núñez; Gabriela Martín; Claudia Cocca; Nora Mohamad; Alicia Gutiérrez; Graciela Cricco; Vanina Medina; Elena Rivera; Máximo Croci; Ernesto Crescenti; Rosa Bergoc
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

Review 6.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 7.  Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.

Authors:  Rupal Dumasia; Kim A Eagle; Eva Kline-Rogers; Niquole May; Leslie Cho; Debabrata Mukherjee
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2005-10

8.  Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart.

Authors:  Peiyong Wang; Jian Liu; Yuquan Li; Sijie Wu; Jinwen Luo; Huan Yang; Ramasamy Subbiah; John Chatham; Olga Zhelyabovska; Qinglin Yang
Journal:  Circ Res       Date:  2010-01-14       Impact factor: 17.367

9.  Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.

Authors:  Romana S Mughal; Philip Warburton; David J O'Regan; Stephen G Ball; Neil A Turner; Karen E Porter
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-08       Impact factor: 2.557

10.  Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

Authors:  Barbara Brunmair; Katrin Staniek; Florian Gras; Nicole Scharf; Aleksandra Althaym; Renate Clara; Michael Roden; Erich Gnaiger; Hans Nohl; Werner Waldhäusl; Clemens Fürnsinn
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more
  20 in total

1.  Noncoding RNAs regulating cardiac muscle mass.

Authors:  Glenn D Wadley; Séverine Lamon; Sarah E Alexander; Julie R McMullen; Bianca C Bernardo
Journal:  J Appl Physiol (1985)       Date:  2018-12-20

2.  Adipocyte-specific loss of PPARγ attenuates cardiac hypertrophy.

Authors:  Xi Fang; Matthew J Stroud; Kunfu Ouyang; Li Fang; Jianlin Zhang; Nancy D Dalton; Yusu Gu; Tongbin Wu; Kirk L Peterson; Hsien-Da Huang; Ju Chen; Nanping Wang
Journal:  JCI Insight       Date:  2016-10-06

Review 3.  Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.

Authors:  Robert B Cameron; Craig C Beeson; Rick G Schnellmann
Journal:  J Med Chem       Date:  2016-09-27       Impact factor: 7.446

4.  Effect of fabrication parameters on morphology and drug loading of polymer particles for rosiglitazone delivery.

Authors:  Madeline R Spetz; Christopher Isely; R Michael Gower
Journal:  J Drug Deliv Sci Technol       Date:  2021-07       Impact factor: 5.062

Review 5.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Authors:  Raymond E Soccio; Eric R Chen; Mitchell A Lazar
Journal:  Cell Metab       Date:  2014-09-18       Impact factor: 27.287

Review 6.  The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

Authors:  Charikleia Kalliora; Konstantinos Drosatos
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

7.  Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.

Authors:  Chang Liu; Tingting Feng; Ningyu Zhu; Peng Liu; Xiaowan Han; Minghua Chen; Xiao Wang; Ni Li; Yongzhen Li; Yanni Xu; Shuyi Si
Journal:  Sci Rep       Date:  2015-04-01       Impact factor: 4.379

8.  Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.

Authors:  Elena Matsa; Paul W Burridge; Kun-Hsing Yu; John H Ahrens; Vittavat Termglinchan; Haodi Wu; Chun Liu; Praveen Shukla; Nazish Sayed; Jared M Churko; Ningyi Shao; Nicole A Woo; Alexander S Chao; Joseph D Gold; Ioannis Karakikes; Michael P Snyder; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2016-08-18       Impact factor: 24.633

Review 9.  Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.

Authors:  D Alemán-González-Duhart; F Tamay-Cach; S Álvarez-Almazán; J E Mendieta-Wejebe
Journal:  PPAR Res       Date:  2016-05-23       Impact factor: 4.964

10.  Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus.

Authors:  Jie-Ming Nie; Hai-Feng Li
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.